Key result
Anatolian Syncope Rule predicts 7-day serious outcomes with ~97% sensitivity.
Why the study?
Existing syncope risk scores have uncertain efficacy in predicting short-term serious outcomes in the Turkish population, motivating comparison and development of a local risk score.
Cohort (n=231)
Blinded to study protocol
No
Effect estimate: Sensitivity 97% (95% CI 0.85-1.00)
Absolute Event Rate: 97% vs 87%
May aid ED syncope risk stratification; leaves open need for prospective validation before practice change.
BACKGROUND: We wished to compare the San Francisco Syncope Rule (SFSR), Evaluation of Guidelines in Syncope Study (EGSYS) and the Osservatorio Epidemiologico sulla Sincope nel Lazio (OESIL) risk scores and to assess their efficacy in recognising patients with syncope at high risk for short-term adverse events (death, the need for major therapeutic procedures, and early readmission to the hospital). We also wanted to test those variables to designate a local risk score, the Anatolian Syncope Rule (ASR). METHODS: This prospective, cohort study was conducted at the emergency department of a tertiary care centre. Between December 1 2009 and December 31 2010, we prospectively collected data on patients of ages 18 and over who presented to the emergency department with syncope. RESULTS: We enrolled 231 patients to the study. A univariate analysis found 23 variables that predicted syncope with adverse events. Dyspnoea, orthostatic hypotension, precipitating cause of syncope, age over 58 years, congestive heart failure, and electrocardiogram abnormality (termed DO-PACE) were found to predict short-term serious outcomes by logistic regression analysis and these were used to compose the ASR. The sensitivity of ASR, OESIL, EGSYS and SFSR for mortality were 100% (0.66 to 1.00); 90% (0.54 to 0.99), 80% (0.44 to 0.97) and 100% (0.66 to 1.00), respectively. The specificity of ASR, OESIL, EGSYS and SFSR for mortality were 78% (0.72 to 0.83); 76% (0.70 to 0.82); 80% (0.74 to 0.85) and 70% (0.63 to 0.76). The sensitivity of ASR, OESIL, EGSYS and SFSR for any adverse event were 97% (0.85 to 1.00); 70% (0.52 to 0.82); 56% (0.40 to 0.72) and 87% (0.72 to 0.95). The specificity of ASR, OESIL, EGSYS and SFSR for any adverse event were 72% (0.64 to 0.78); 82% (0.76 to 0.87); 84% (0.78 to 0.89); 78% (0.71 to 0.83), respectively. CONCLUSION: The newly proposed ASR appears to be highly sensitive for identifying patients at risk for short-term serious outcomes, with scores at least as good as those provided by existing diagnostic rules, and it is easier to perform at the bedside within the Turkish population. If prospectively validated, it may offer a tool to aid physicians' decision-making.
No takes yet. Share an insight, caveat, or question.
Kayayurt et al. (2012) conducted a cohort in Syncope (n=231). Anatolian Syncope Rule (ASR) vs. OESIL, EGSYS, and SFSR risk scores was evaluated on Sensitivity for any adverse event within 7 days (Sensitivity 97%, 95% CI 0.85-1.00). The newly proposed Anatolian Syncope Rule (ASR) demonstrated 97% sensitivity and 72% specificity for predicting short-term serious outcomes within 7 days after syncope.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: